Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.
مجلة كلية الطب, 2015 Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can ...
Mohammed A. Al-Karkhi +2 more
doaj +1 more source
Clinical performance of an infliximab rapid quantification assay [PDF]
, 2017 Background: Therapeutic drug monitoring (TDM)-based algorithms can be used to guide infliximab (IFX) adjustments in inflammatory bowel disease (IBD) patients.
Afonso, Joana +21 more
core +2 more sources
Viewpoint on handling anti-TNF failure in psoriasis [PDF]
, 2013 An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core +1 more source
Infliximab for the treatment of fistulas in patients with Crohn's disease.
New England Journal of Medicine, 1999 BACKGROUND Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor alpha, has recently been developed as a treatment for Crohn's disease.
Tephan +18 more
semanticscholar +1 more source
Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab [PDF]
Journal of Clinical & Experimental Dermatology Research, 2014 Background: Infliximab is the fastest acting biological agent in psoriasis treatment due to the possibility of intravenous administration and a well-conducted induction phase of treatment (week 0, 2, and 6). Another advantage is the weight-based dosing.
Peter Kozub +3 more
openaire +2 more sources
In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis [PDF]
, 2015 Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncaseating granulomas involving intrathoracic lymph nodes and lung parenchyma.
BRUNO, PIERDONATO +9 more
core +5 more sources
Gastroenterology, 2019 BACKGROUND & AIMS Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies.
A. Sazonovs +153 more
semanticscholar +1 more source
DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis [PDF]
, 2005 The Disease Activity Score using 28 joint counts (DAS28) has been developed in a cohort of patients with rheumatoid arthritis in which only conventional anti-rheumatic treatments were used. It has extensively been validated to monitor disease activity in
Fransen, Jaap, van Riel, Piet LCM
core +2 more sources
Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]
, 2020 Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra +3 more
core +1 more source
BMJ Open Gastroenterology, 2021 Background Infliximab is an efficacious therapy for inflammatory bowel disease and may play a role in management of some extraintestinal manifestations.
Daniel J Stein +6 more
doaj +1 more source